Trial Profile
An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Lisavanbulin (Primary)
- Indications Cholangiocarcinoma; Glioblastoma; Glioma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Basilea Pharmaceutica
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 08 Mar 2023 Status has been changed to discontinued.
- 08 Mar 2023 Results from phase 2, presented at the 21st International Congress on Targeted Anticancer Therapies